NASDAQ:PETX - Aratana Therapeutics Stock Price, News & Analysis

$4.92
0.00 (0.00 %)
(As of 08/23/2019 06:00 AM ET)
Today's Range
$4.92
Now: $4.92
$4.92
50-Day Range
$4.92
MA: $4.96
$5.23
52-Week Range
$3.30
Now: $4.92
$7.16
VolumeN/A
Average Volume1.03 million shs
Market Capitalization$241.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.41 million
Book Value$2.07 per share

Profitability

Net Income$-14,720,000.00

Miscellaneous

Employees83
Market Cap$241.08 million
Next Earnings DateN/A
OptionableOptionable

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.


Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analysts' expectations of $5.70 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. View Aratana Therapeutics' Earnings History.

What price target have analysts set for PETX?

4 brokerages have issued 1-year price targets for Aratana Therapeutics' shares. Their predictions range from $4.14 to $5.00. On average, they anticipate Aratana Therapeutics' share price to reach $4.7250 in the next year. This suggests that the stock has a possible downside of 4.0%. View Analyst Price Targets for Aratana Therapeutics.

What is the consensus analysts' recommendation for Aratana Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics.

Has Aratana Therapeutics been receiving favorable news coverage?

Media stories about PETX stock have been trending positive on Friday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Aratana Therapeutics.

Who are some of Aratana Therapeutics' key competitors?

What other stocks do shareholders of Aratana Therapeutics own?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)
  • Ms. Rhonda L. Hellums, CFO & Treasurer (Age 47)
  • Mr. John C. Ayres J.D., VP of Corp. Devel. and Admin., Gen. Counsel & Sec. (Age 40)
  • Mr. Brent A. Standridge, Consultant (Age 61)
  • Ms. Rachel Reiff, Head of Corp. Communications

Who are Aratana Therapeutics' major shareholders?

Aratana Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.63%), Man Group plc (5.58%), Alpine Associates Management Inc. (4.89%), Water Island Capital LLC (2.90%), Vanguard Group Inc. (2.74%) and OMERS ADMINISTRATION Corp (2.03%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Which major investors are selling Aratana Therapeutics stock?

PETX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Bank of Montreal Can, State Board of Administration of Florida Retirement System and BNP Paribas Arbitrage SA. Company insiders that have sold Aratana Therapeutics company stock in the last year include Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Which major investors are buying Aratana Therapeutics stock?

PETX stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Alpine Associates Management Inc., Water Island Capital LLC, OMERS ADMINISTRATION Corp, Gabelli Funds LLC, Polar Asset Management Partners Inc., GABELLI & Co INVESTMENT ADVISERS INC. and SG Americas Securities LLC. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $4.92.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $241.08 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 83 workers across the globe.View Additional Information About Aratana Therapeutics.

What is Aratana Therapeutics' official website?

The official website for Aratana Therapeutics is http://www.aratana.com/.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  382 (Thanks for Voting!)
Underperform Votes:  259 (Thanks for Voting!)
Total Votes:  641
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel